TiGenix | 4biocapital

top of page

HOME
ABOUT US
- SOCIAL IMPACT
STRATEGY
TEAM
PORTFOLIO
- VENTURE PORTFOLIO
- PAST PORTFOLIO
4BATLE ICAV
NEWSROOM
CONTACT
More

Use tab to navigate through the menu items.

NEWSROOM

Mar 24, 2018

TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval

TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval

Jan 5, 2018

Takeda announces its intention to acquire TiGenix

Takeda announces its intention to acquire TiGenix

ARCHIVE

December 2022
November 2022
October 2022
September 2022
June 2022
April 2022
March 2022
February 2022
January 2022
December 2021
October 2021
April 2021
March 2021
January 2021
December 2020
November 2020
October 2020
July 2020
June 2020
May 2020

SEARCH BY TAGS

FOLLOW US

4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764)

4BIO Partners LLP is an SEC Registered Investment Advisor number 801-121342

© 2015-2022 by 4BIO Partners LLP

bottom of page